Ninlaro 2.3 mg. 3 mg & 4 mg Hard capsule.
PDF Leaflet Revision Date: 4 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with recurrent or relapsed multiple myeloma.
Dosage (summary)
4 mg orally once a week on Days 1, 8, and 15 of a 28-day cycle.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding.
Key Drug Interactions
- Strong CYP3A inducers
- Oral contraceptives
Contraindications
- Hypersensitivity to ixazomib or excipients
Common side effects
- Diarrhoea
- Thrombocytopaenia
- Neutropenia
- Peripheral neuropathy
- Nausea
Counselling Points
- Take at least 1 hour before or 2 hours after food.
- Monitor for signs of thrombocytopaenia.
- Use effective contraception during treatment.
Serious warnings
- Thrombocytopaenia
- Gastrointestinal toxicities
- Peripheral neuropathy
- Severe cutaneous adverse reactions
- Thrombotic microangiopathy
Important Disclaimer
The Ninlaro 2.3 mg. 3 mg & 4 mg Hard capsule. professional information leaflet below is the property of Takeda and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
